Low Doses of Nonylphenol Promote Growth of Colon Cancer Cells through Activation of ERK1/2 via G Protein–Coupled Receptor 30
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Nonylphenol (NP) is an endocrine disruptor found in products such as cleaners, plastics, and detergents. It exerts actions similar to endogenous 17-estradiol (E2) and is reported to influence various cancers. However, its role in colon cancer remains elusive. Materials and Methods Colon cancer cell lines COLO 205 and SW480 were employed in our study. The cells were treated with NP or E2 followed by measurement of apoptosis and proliferation using flow cytometry and MTT assays, respectively. G protein–coupled estrogen receptor 30 (GPR30) expression was visualized using immunofluorescence and Western blot. To investigate the underlying mechanism, the expression levels of GPR30, p-protein kinase A (PKA), c-myc, cyclin D1, and ERK1/2 were analyzed using Western blot. Meanwhile, the GPR30 antagonist G15 was utilized to validate the role of GPR30 in colon cancer progression. Finally, the effect of a GPR30 inhibitor on tumor growth was determined in vivo using tumor xenograft mouse models. Results NP facilitated the proliferation of colon cancer cells and induced apoptosis failure in vitro. Western blot revealed increased GPR30 expression levels in response to NP treatment. Cyclin D1, p-PKA, c-myc, and proliferating cell nuclear antigen, proteins that regulate the cell cycle, were all upregulated by NP, and NP-mediated ERK1/2 activation and subsequent cell proliferation were abrogated by the GPR30 inhibitor G15. Moreover, colon cancer mice that received G15 administration demonstrated impaired tumor growth in vivo. Conclusion Low dose NP promotes the growth of colon tumors through GPR30-mediated activation of ERK1/2 signaling.
Abstract
Purpose Nonylphenol (NP) is an endocrine disruptor found in products such as cleaners, plastics, and detergents. It exerts actions similar to endogenous 17-estradiol (E2) and is reported to influence various cancers. However, its role in colon cancer remains elusive. Materials and Methods Colon cancer cell lines COLO 205 and SW480 were employed in our study. The cells were treated with NP or E2 followed by measurement of apoptosis and proliferation using flow cytometry and MTT assays, respectively. G protein–coupled estrogen receptor 30 (GPR30) expression was visualized using immunofluorescence and Western blot. To investigate the underlying mechanism, the expression levels of GPR30, p-protein kinase A (PKA), c-myc, cyclin D1, and ERK1/2 were analyzed using Western blot. Meanwhile, the GPR30 antagonist G15 was utilized to validate the role of GPR30 in colon cancer progression. Finally, the effect of a GPR30 inhibitor on tumor growth was determined in vivo using tumor xenograft mouse models. Results NP facilitated the proliferation of colon cancer cells and induced apoptosis failure in vitro. Western blot revealed increased GPR30 expression levels in response to NP treatment. Cyclin D1, p-PKA, c-myc, and proliferating cell nuclear antigen, proteins that regulate the cell cycle, were all upregulated by NP, and NP-mediated ERK1/2 activation and subsequent cell proliferation were abrogated by the GPR30 inhibitor G15. Moreover, colon cancer mice that received G15 administration demonstrated impaired tumor growth in vivo. Conclusion Low dose NP promotes the growth of colon tumors through GPR30-mediated activation of ERK1/2 signaling.
참고문헌 (29)
- Liu MM, "Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression", J Biol Chem, 277, pp.24353~24360 (2002)
- Prossnitz ER, "GPR30: a G protein-coupled receptor for estrogen", Mol Cell Endocrinol, 265-266, pp.138~142 (2007)
- Filardo EJ, "Estrogen action via the G protein-coupled receptor, GPR30 : stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis", Mol Endocrinol, 16, pp.70~84 (2002)
- Kanda N, "17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2expression", J Invest Dermatol, 121, pp.1500~1509 (2003)
- Maggiolini M, "The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells", J Biol Chem, 279, pp.27008~27016 (2004)
- Caiazza F, "17Beta-estradiol induces ERbeta up-regulation via p38", MAPK activation in colon cancer cells, 2007, pp.359, 102~107
- Barzi A, "Molecular pathways : estrogen pathway in colorectal cancer", Clin Cancer Res, 19, pp.5842~5848 (2013)
- Wetherill YB, "In vitro molecular mechanisms of bisphenol A action", Reprod Toxicol, 24, pp.178~198 (2007)
- Fernandez SV, "Estrogen and xenoestrogens in breast cancer", Toxicol Pathol, 38, pp.110~122 (2010)
- Lee JW, "Nonylphenol increases tumor formation and growth by suppressing gender-independent lymphocyte proliferation and macrophage activation", Environ Toxicol, 32, pp.1679~1687 (2017)
- Kim SH, "Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells", Toxicol In Vitro, 32, pp.240~247 (2016)
- Konstantinopoulos PA, "Oestrogen receptor beta(ERbeta)is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation", Eur J Cancer, 39, pp.1251~1258 (2003)
- Campbell-Thompson M, "Expression of estrogen receptor(ER)subtypes and ERbeta isoforms in colon cancer", Cancer Res, 61, pp.632~640 (2001)
- Prossnitz ER, "GPR30 : a novel therapeutic target in estrogen-related disease", Trends Pharmacol Sci, 29, pp.116~123 (2008)
- He YY, "Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK", ERK mitogen-activated protein kinase pathway, 2009, pp.100, 1051~1061
- Kleuser B, "17-Betaestradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30", Mol Pharmacol, 74, pp.1533~1543 (2008)
- Chakrabarti S, "G-protein coupled receptor 30(GPR30): a novel regulator of endothelial inflammation", PLoS One, 7, pp.e52357~ (2012)
- Ge LC, "Involvement of activating ERK1", 2 through G protein coupled receptor 30 and estrogen receptor α, Toxicol Lett, pp.2014, 226[DOI]
- Mo Z, "GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer", Breast Cancer Res, 15, pp.R114~ (2013)
- Arias-Pulido H, "GPR30 and estrogen receptor expression : new insights into hormone dependence of inflammatory breast cancer", Breast Cancer Res Treat, 123, pp.51~58 (2010)
- Jala VR, "Enhanced expression of G-protein coupled estrogen receptor(GPER", GPR30)in lung cancer, 2012, pp.12, 624~
- He YY, "Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2", J Cancer Res Clin Oncol, 138, pp.775~783 (2012)
- Qiu Y, "Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta", J Endocrinol, 174, pp.369~377 (2002)
- Marino M, "Estrogen signaling multiple pathways to impact gene transcription", Curr Genomics, 7, pp.497~508 (2006)
- Filardo E, "Activation of the novel estrogen receptor G protein-coupled receptor 30(GPR30)at the plasma membrane", Endocrinology, 148, pp.3236~3245 (2007)
- Bustos V, "GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions", Oncotarget, 8, pp.84258~84275 (2017)
- Recchia AG, "Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha", Food Addit Contam, 21, pp.134~144 (2004)
- Nguyen-Vu T, "Estrogen receptor beta reduces colon cancer metastasis through a novel miR-205 : PROX1 mechanism", Oncotarget, 7, pp.42159~42171 (2016)
- Hartman J, "Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells", Cancer Res, 69, pp.6100~6106 (2009)